Cellivery Proves Efficacy of Parkinson's Disease Drug iCP-Parkin in Alzheimer's Disease Treatment

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced that it has successfully demonstrated the therapeutic efficacy mechanism of iCP-Parkin, which is being developed as a treatment for Alzheimer’s Disease (AD) using the TSDT platform, a pharmacological substance delivery technology within the body, originally developed for Parkinson’s Disease (PD).

Previously known candidate substances for degenerative brain disease treatments had limitations as fundamental therapies because they could not be directly delivered inside brain nerve cells due to low blood-brain barrier (BBB) permeability. iCP-Parkin has the same beta-amyloid aggregate removal mechanism (97%) as Aducanumab and also exhibits neuroprotective effects. Despite being a large molecular recombinant protein therapeutic, the company explained that by utilizing the TSDT platform technology, its blood-brain barrier and brain nerve cell permeability are higher than those of general monoclonal antibody therapeutics.

A Cellivery official stated, "Generally, monoclonal antibody and bispecific antibody therapeutics are reported to have blood-brain barrier permeability of about 0.1~0.2%, up to a maximum of 0.5%," adding, "Antibody therapeutics developed for degenerative brain diseases are generally evaluated as having low therapeutic efficacy even when administered in large amounts."

He said, "In the primary blood-brain barrier permeability analysis of iCP-Parkin in an Alzheimer’s disease animal model, it showed an excellent blood-brain barrier permeability of about 3%, which is up to approximately 30 times higher delivery capability compared to general antibody therapeutics," and added, "To confirm this more precisely, we are currently conducting detailed analyses on brain and blood samples from 150 Alzheimer’s disease dementia animals each in the UK, and based on the comprehensive data, we expect the permeability to be around 10%."

The company stated, "Top 30 global pharmaceutical companies such as Biogen, Pfizer, Novartis, AbbVie, Sanofi, and Eli Lilly have already requested in-depth discussions regarding the TSDT platform-based blood-brain barrier permeability technology to enhance the therapeutic efficacy of their brain disease pipelines," emphasizing, "Based on the blood-brain barrier permeability analysis results, we plan to actively promote licensing of the TSDT platform technology and iCP-Parkin at BIO International 2021, which will be held from the 14th to the 18th."